Toll-Like Receptor 7-Targeted Therapy in Respiratory Disease

Katie M. Lebold, David Jacoby, Matthew Drake

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Allergic asthma and allergic rhinitis are inflammatory diseases of the respiratory tract characterized by an excessive type-2 T helper cell (Th2) immune response. Toll-like receptor 7 (TLR7) is a single-stranded viral RNA receptor expressed in the airway that initiates a Th1 immune response and has garnered interest as a novel therapeutic target for treatment of allergic airway diseases. In animal models, synthetic TLR7 agonists reduce airway hyperreactivity, eosinophilic inflammation, and airway remodeling while decreasing Th2-associated cytokines. Furthermore, activation of TLR7 rapidly relaxes airway smooth muscle via production of nitric oxide. Thus, TLR7 has dual bronchodilator and anti-inflammatory effects. Two TLR7 ligands with promising pharmacologic profiles have entered clinical trials for the treatment of allergic rhinitis. Moreover, TLR7 agonists are potential antiviral therapies against respiratory viruses. TLR7 agonists enhance influenza vaccine efficacy and also reduce viral titers when given during an active airway infection. In this review, we examine the current data supporting TLR7 as a therapeutic target in allergic airway diseases.

Original languageEnglish (US)
Pages (from-to)114-119
Number of pages6
JournalTransfusion Medicine and Hemotherapy
Volume43
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Toll-Like Receptor 7
Respiratory Therapy
Airway Remodeling
Respiratory Tract Diseases
Th2 Cells
Influenza Vaccines
Bronchodilator Agents
Viral RNA
Therapeutics
Antiviral Agents
Smooth Muscle
Nitric Oxide
Anti-Inflammatory Agents
Asthma
Animal Models
Clinical Trials
Cytokines
Ligands
Viruses
Inflammation

Keywords

  • Allergic rhinitis
  • Asthma
  • Toll-like receptor 7
  • Virus infection

ASJC Scopus subject areas

  • Hematology
  • Immunology and Allergy

Cite this

Toll-Like Receptor 7-Targeted Therapy in Respiratory Disease. / Lebold, Katie M.; Jacoby, David; Drake, Matthew.

In: Transfusion Medicine and Hemotherapy, Vol. 43, No. 2, 01.03.2016, p. 114-119.

Research output: Contribution to journalArticle

@article{72e0b3dcca7c482d948517df008f5cb3,
title = "Toll-Like Receptor 7-Targeted Therapy in Respiratory Disease",
abstract = "Allergic asthma and allergic rhinitis are inflammatory diseases of the respiratory tract characterized by an excessive type-2 T helper cell (Th2) immune response. Toll-like receptor 7 (TLR7) is a single-stranded viral RNA receptor expressed in the airway that initiates a Th1 immune response and has garnered interest as a novel therapeutic target for treatment of allergic airway diseases. In animal models, synthetic TLR7 agonists reduce airway hyperreactivity, eosinophilic inflammation, and airway remodeling while decreasing Th2-associated cytokines. Furthermore, activation of TLR7 rapidly relaxes airway smooth muscle via production of nitric oxide. Thus, TLR7 has dual bronchodilator and anti-inflammatory effects. Two TLR7 ligands with promising pharmacologic profiles have entered clinical trials for the treatment of allergic rhinitis. Moreover, TLR7 agonists are potential antiviral therapies against respiratory viruses. TLR7 agonists enhance influenza vaccine efficacy and also reduce viral titers when given during an active airway infection. In this review, we examine the current data supporting TLR7 as a therapeutic target in allergic airway diseases.",
keywords = "Allergic rhinitis, Asthma, Toll-like receptor 7, Virus infection",
author = "Lebold, {Katie M.} and David Jacoby and Matthew Drake",
year = "2016",
month = "3",
day = "1",
doi = "10.1159/000445324",
language = "English (US)",
volume = "43",
pages = "114--119",
journal = "Transfusion Medicine and Hemotherapy",
issn = "1660-3796",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Toll-Like Receptor 7-Targeted Therapy in Respiratory Disease

AU - Lebold, Katie M.

AU - Jacoby, David

AU - Drake, Matthew

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Allergic asthma and allergic rhinitis are inflammatory diseases of the respiratory tract characterized by an excessive type-2 T helper cell (Th2) immune response. Toll-like receptor 7 (TLR7) is a single-stranded viral RNA receptor expressed in the airway that initiates a Th1 immune response and has garnered interest as a novel therapeutic target for treatment of allergic airway diseases. In animal models, synthetic TLR7 agonists reduce airway hyperreactivity, eosinophilic inflammation, and airway remodeling while decreasing Th2-associated cytokines. Furthermore, activation of TLR7 rapidly relaxes airway smooth muscle via production of nitric oxide. Thus, TLR7 has dual bronchodilator and anti-inflammatory effects. Two TLR7 ligands with promising pharmacologic profiles have entered clinical trials for the treatment of allergic rhinitis. Moreover, TLR7 agonists are potential antiviral therapies against respiratory viruses. TLR7 agonists enhance influenza vaccine efficacy and also reduce viral titers when given during an active airway infection. In this review, we examine the current data supporting TLR7 as a therapeutic target in allergic airway diseases.

AB - Allergic asthma and allergic rhinitis are inflammatory diseases of the respiratory tract characterized by an excessive type-2 T helper cell (Th2) immune response. Toll-like receptor 7 (TLR7) is a single-stranded viral RNA receptor expressed in the airway that initiates a Th1 immune response and has garnered interest as a novel therapeutic target for treatment of allergic airway diseases. In animal models, synthetic TLR7 agonists reduce airway hyperreactivity, eosinophilic inflammation, and airway remodeling while decreasing Th2-associated cytokines. Furthermore, activation of TLR7 rapidly relaxes airway smooth muscle via production of nitric oxide. Thus, TLR7 has dual bronchodilator and anti-inflammatory effects. Two TLR7 ligands with promising pharmacologic profiles have entered clinical trials for the treatment of allergic rhinitis. Moreover, TLR7 agonists are potential antiviral therapies against respiratory viruses. TLR7 agonists enhance influenza vaccine efficacy and also reduce viral titers when given during an active airway infection. In this review, we examine the current data supporting TLR7 as a therapeutic target in allergic airway diseases.

KW - Allergic rhinitis

KW - Asthma

KW - Toll-like receptor 7

KW - Virus infection

UR - http://www.scopus.com/inward/record.url?scp=84968735543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84968735543&partnerID=8YFLogxK

U2 - 10.1159/000445324

DO - 10.1159/000445324

M3 - Article

AN - SCOPUS:84968735543

VL - 43

SP - 114

EP - 119

JO - Transfusion Medicine and Hemotherapy

JF - Transfusion Medicine and Hemotherapy

SN - 1660-3796

IS - 2

ER -